Phase 1b/2 Study of Futibatinib in Combination With Binimetinib in Patients With Advanced KRAS Mutant Cancer
Advanced or Metastatic Solid Tumors Irrespective of Gene Alterations Non-Small Cell Lung Cancer KRAS Gene Mutation Futibatinib Binimetinib MEKi FGFR FGFRi TAS-120 KRASmt NSCLC Carcinoma, Non-Small-Cell Lung Futibatinib and Binimetinib
Lead Scientist at University of California Health
- Lee Rosen (ucla)
HS Clinical Professor, Medicine. Authored (or co-authored) 106 research publications.
- accepting new patients
- Start Date
- Completion Date
- Taiho Oncology, Inc.
- Phase 1/2
- Study Type
- Last Updated